MARKET

AXDX

AXDX

Accelerate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.19
-0.20
-2.71%
After Hours: 7.00 -0.19 -2.64% 19:56 05/10 EDT
OPEN
7.26
PREV CLOSE
7.39
HIGH
7.35
LOW
6.80
VOLUME
247.70K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
6.80
MARKET CAP
450.20M
P/E (TTM)
-5.1442
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Monday
  Monday morning saw 78 companies set new 52-week lows.
Benzinga · 10h ago
--Piper Sandler Adjusts Price Target on Accelerate Diagnostics to $9 From $12, Maintains Overweight Rating
MT Newswires · 16h ago
10-Q: ACCELERATE DIAGNOSTICS, INC
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Introductory Note Except as...
Edgar Online - (EDG = 10Q, 10K) · 3d ago
DJ Accelerate Diagnostics, Inc. CEO Jack Phillips on Q1 2021 Results -- Earnings Call Transcript >AXDX
Dow Jones · 3d ago
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 4d ago
Accelerate Diagnostics Q1 EPS $(0.41) Down From $(0.39) YoY, Sales $2.52M Up From $2.34M YoY
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.41) per share. This is a 5.13 percent decrease over losses of $(0.39) per share from the same period last year. The company reported $2.52 million in
Benzinga · 4d ago
8-K: Accelerate Diagnostics, Inc
(EDGAR Online via COMTEX) -- 0000727207 false 0000727207 2021-05-06 2021-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Accelerate Diagnostics EPS misses by $0.08, misses on revenue
Accelerate Diagnostics (AXDX): Q1 GAAP EPS of -$0.41 misses by $0.08.Revenue of $2.5M (+6.8% Y/Y) misses by $0.75M.Ended the first quarter with 274 U.S. clinically live and revenue-generating instruments, with
Seekingalpha · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXDX. Analyze the recent business situations of Accelerate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXDX stock price target is 13.00 with a high estimate of 17.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 166
Institutional Holdings: 31.55M
% Owned: 50.39%
Shares Outstanding: 62.62M
TypeInstitutionsShares
Increased
41
993.27K
New
16
697.52K
Decreased
24
1.53M
Sold Out
13
1.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.40%
Healthcare Equipment & Supplies
-1.41%
Key Executives
Chairman/Independent Director
John Patience
President/Chief Executive Officer/Director
John Phillips
Chief Financial Officer
Steve Reichling
Other
Ron Price
Independent Director
Thomas Brown
Other
Nedal Safwat
Independent Director
Roland Diggelmann
Independent Director
Tom Brown
Independent Director
Louise Francesconi
Independent Director
Mark Miller
Independent Director
Jack Schuler
Independent Director
Matthew Strobeck
Independent Director
Frank Ten Brink
Independent Director
Charles Watts
Independent Director
Frank ten Brink
No Data
  • All
  • Financials
  • Insiders
More
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Webull offers kinds of Accelerate Diagnostics Inc stock information, including NASDAQ:AXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXDX stock methods without spending real money on the virtual paper trading platform.